Mehmet Kemal Samur

Biography

Publications

• CRISPR-Cas13d functional transcriptomics reveals widespread isoform-selective cancer dependencies on lncRNAs.

  Morelli E, Aktas Samur A, Maisano D, Gao C, Favasuli VK, Papaioannou D, De Nola G, Henninger JE, Liu N, Turi M, Folino P, Vreux L, Cumerlato M, Chen L, Aifantis I, Fulciniti M, Anderson KC, Lytton-Jean AK, Gulla A, Young R, Samur MK, Munshi NC. Blood 2025 May 22

  PMID: 40403231

• Targeting Acetyl-CoA Carboxylase Suppresses De Novo Lipogenesis and Tumor Cell Growth in Multiple Myeloma.

  Morelli E, Ribeiro CF, Rodrigues SD, Gao C, Socciarelli F, Maisano D, Favasuli V, Liu N, Todoerti K, Chakraborty C, Yao Y, Fulciniti M, Samur M, Aktas-Samur A, Amodio N, Turi M, Barello F, Penailillo J, Giallongo C, Romano A, Gulla A, Anderson KC, Inghirami G, Munshi NC, Loda M. Clin Cancer Res 2025 May 15

  PMID: 40053701

• Editor's Note: Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells.

  Das DS, Das A, Ray A, Song Y, Samur MK, Munshi NC, Chauhan D, Anderson KC. Clin Cancer Res 2025 May 15

  PMID: 40370044

• The mitochondrial protease ClpP is a metabolic vulnerability and an immunogenic trigger against multiple myeloma.

  Perini T, Zordan P, Del Pizzo R, Resnati M, Viviani L, Stefanoni D, Cassina L, Orfanelli UP, Trudu M, Oliva L, Lacidogna D, Samur MK, Materozzi M, Drago D, Andolfo A, Patrone M, Degano M, Boletta A, Milan E, Ciceri F, Munshi NC, Bellone M, Cenci S. Blood 2025 Apr 29

  PMID: 40300074

• Immune profiling of smoldering multiple myeloma patients treated in a phase lb study of PVX-410 vaccine targeting XBP1/CD138/CS1 antigens, and citarinostat, a histone deacetylase inhibitor (HDACi) with and without lenalidomide.

  Cirstea D, Shome R, Samur M, Talluri S, Connolly JJ, Wright AJ, Duvallet E, Joyce ANR, Lively K, Basinsky G, Yee AJ, Chase CC, Malek E, Niesvizky R, Richardson PG, Raje NS. Blood Cancer J 2025 Apr 24

  PMID: 40274800